Table 2.
Changes in gout patients during the SARS-CoV-2 pandemic
| Pre-pandemic evaluation n=71 |
Pandemic evaluation n=71 |
p ∞ | |
|---|---|---|---|
|
Flare (%) Intercritical gout (%) |
4.4Ω 95.6Ω |
35 65 |
0.01 |
| Flares last 6 months, median [IQR] | 0 [0–1.4] | 1 [0–10] | 0.004 |
| Urate mg/dL, mean (SD) | 5.6 (1.7) | 6.7 (2.2) | 0.016 |
| Limited to motion joints. median [IQR] | 0 [0–10] | 0 [0–3.1] | 0.005 |
| HAQ score, median [IQR] | 0.1 [1–2.9] | 0 [0–0.47] | 0.001 |
| Urate-lowering therapy (% )¥ | 93 | 90 | 0.30 |
| Allopurinol mg/day, mean (SD) | 472.5 (262.3) | 404.8 (244) | 0.36 |
| Colchicine, prophylaxis (%) | 35 | 17 | 0.065 |
| BMI, mean (SD) | 29.4 (4.9) | 29.7 (4.9) | 0.86 |
| MDRD mL/min, mean (SD) | 76.2 (28) | 69.9 (25.7) | 0.51 |
ΩPercentage of patients evaluated as flares or intercritical gout from our cohort in the evaluations 6 months before March 16, 2020
¥ULT: Allopurinol n=90, febuxostat n=3. ∞Paired t-test, Wilcoxon and chi-square test